3.
纳入研究的干预措施及结局指标
Inventions and endpoint of included trials
| Study | Invention group | Case | Endpoint | |||||
| Experimental | Control | Experimental | Control | |||||
| NPE: Vinorelbine+Oxaliplatin+rh-endostatin; NOE: Vinorelbine+Oxaliplatin+rh-endostatin; GPE: Gemcitabine+Cisplatin+rh-endostatin; TCE: Paclitaxel+Carboplatin+rh-endostatin; NP: Vinorelbine+Oxaliplatin; NO: Vinorelbine+Oxaliplatin; GP: Gemcitabine+Cisplatin; TC: Paclitaxel +Carboplatin; T: Paclitaxel; RT: radiotherapy; RR: response rate; SI：symptom improvement. | ||||||||
| Yang L[23] | NPE | NP | 54 | 33 | RR, SI, Adverse reactions | |||
| Wang JW[20] | NPE | NP+placebo | 322 | 164 | RR, SI, Adverse reactions | |||
| Huang C[18] | NPE | NP | 50 | 24 | RR, Survival rate, Adverse reactions | |||
| Chen SJ[10] | NOE | NO | 24 | 26 | RR, Adverse reactions | |||
| Huang GS[7] | NPE | NP | 20 | 20 | RR, Survival rate, SI, Adverse reactions | |||
| Fan QL[22] | NPE | NP | 20 | 20 | RR, Adverse reactions | |||
| Cai L[13] | NPE | NP | 39 | 32 | RR, Survival rate, SI, Adverse reactions | |||
| XieYR[9] | GPE | GP | 22 | 26 | RR, Survival rate, SI, Adverse reactions | |||
| Liu J[16] | NPE+RT | NP+RT | 31 | 31 | RR, Survival rate, Adverse reactions | |||
| Ma JB[21] | NPE+RT | NP+RT | 23 | 23 | RR, Survival rate, SI, Adverse reactions | |||
| Zhang T[14] | GPE | T | 48 | 56 | RR, SI, Adverse reactions | |||
| Tang Z[8] | TCE | TC | 27 | 26 | RR, Adverse reactions | |||
| Han LC[11] | TPE | TP | 37 | 31 | RR, Adverse reactions | |||
| Jin J[12] | NPE | NP | 15 | 25 | RR, Survival rate, Adverse reactions | |||
| Liu J[15] | TE | T | 30 | 30 | RR, Adverse reactions | |||